The 24 linked references in paper S. Avdeev N., Z. Aisanov R., A. Belevskiy S., A. Vizel' A., S. Zyryanov K., G. Ignatova L., N. Knyazheskaya P., I. Leshchenko V., S. Ovcharenko I., A. Sinopal'nikov I., I. Stepanyan E., V. Trofimov I., С. Авдеев Н., З. Айсанов Р., А. Белевский С., А. Визель А., С. Зырянов К., Г. Игнатова Л., Н. Княжеская П., И. Лещенко В., С. Овчаренко И., А. Синопальников И., И. Степанян Э., В. Трофимов И. (2017) “Новые возможности в профилактике обострений хронической обструктивной болезни легких. Заключение группы специалистов Российского респираторного общества // New opportunities for prevention of exacerbations of chronic obstructive pulmonary disease. Russian Respiratory Society Expert Opinion” / spz:neicon:pulmonology:y:2017:i:1:p:108-113

  1. 17.www.goldcopd.org.Accessed February 26, 2017. 2. Bateman E.D., Ferguson G.T., Barnes N. et al. Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study.Eur. Respir. J.2013; 42 (6): 1484–1494. DOI: 10.1183/09031936.00200212.
  2. Singh D., Jones P.W., Bateman E.D. et al. Efficacy and safety of aclidinium bromide/formoterol fumarate fixeddose combinations compared with individual components and placebo in patients with COPD (ACLIFORM-COPD): a multicentre, randomised study. BMC Pulm. Med.2014; 14: 178. DOI: 10.1186/1471-2466-14-178.
  3. Buhl R., Maltais F., Abrahams R. et al. Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2–4). Eur. Respir. J.2015; 45 (4): 969–979. DOI: 10.1183/09031936.00136014.
  4. Decramer M., Anzueto A., Kerwin E. et al. Efficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: results from two multicentre, blinded, randomised controlled trials. Lancet Respir. Med.2014; 2 (6): 472–486. DOI: 10.1016/ S2213-2600(14)70065-7.
  5. Vogelmeier C.F., Bateman E.D., Pallante J. et al. Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol-fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group study. Lancet Respir. Med.2013; 1 (1): 51–60. DOI: 10.1016/S2213-2600(12)70052-8.
  6. Beeh K.M., Derom E., Echave-Sustaeta J. et al. The lung function profile of once-daily tiotropium and olodaterol via Respimat®is superior to that of twice-daily salmeterol and fluticasone propionate via Accuhaler®(ENERGITO® study).Int. J. Chron. Obstruct. Pulmon. Dis.2016; 11: 193–205. DOI: 10.2147/COPD.S95055.
  7. Singh D., Worsley S., Zhu C.Q. et al. Umeclidinium/ vilanterol versus fluticasone propionate/salmeterol in COPD: a randomised trial. BMC Pulm. Med.2015; 15: 91. DOI: 10.1186/s12890-015-0092-1.
  8. 0–1039. DOI: 10.1183/13993003.00216-2016. 10. Mahler D.A., Decramer M., D'Urzo A. et al. Dual bronchodilation with QVA149 reduces patient-reported dyspnoea in COPD: BLAZE study.Eur. Respir. J. 2014; 43 (6): 1599–1609. DOI: 10.1183/09031936.00124013. (the paper at Socionet)
  9. Chapman K.R., Bateman E.D., Chen H. et al. QVA149 improves lung function, dyspnea, and health status independent of previously prescribed medications and COPD severity: A subgroup analysis from the SHINE and ILLUMINATE studies. J. COPD F.2015; 2 (1): 48–60. DOI: 10.15326.
  10. Wedzicha J.A. et al. Indacaterol–Glycopyrronium versus Salmeterol–Fluticasone for COPD. N. Eng. J. Med.2016; 374 (23): 2222–2234. DOI: 10.1016/S2213-2600(13)70052-3.
  11. Aaron S.D., Vandemheen K.L., Fergusson D. et al. Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomised trial. Ann. Intern. Med. 2007; 146 (8): 545–555. DOI: 10.7326/0003-4819-146-8200704170-00152.
  12. Welte T., Miravitlles M., Hernandez P. et al. Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2009; 180 (8): 741–750. DOI: 10.1164/rccm.200904-0492OC.
  13. Karner C., Cates C.J. Combination inhaled steroid and long-acting beta2-agonist in addition to tiotropium versus tiotropium or combination alone for chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. 2011; (3): CD008532. DOI: 10.1002/14651858.CD008532.pub2.
  14. Singh D., Papi А., Corradi M. et al. Single inhaler triple therapy versus inhaled corticosteroid plus long-acting β2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomized controlled trial. Lancet. 2016; 388: 963–973. DOI: 10.1016/S0140-6736(16)31354-X.
  15. Singh D., Schröder-Babo W., Cohuet G. et al. The bronchodilator effects of extrafine glycopyrronium added to combination treatment with beclometasone dipropionate plus formoterol in COPD: A randomised crossover study (the TRIDENT study). Respir. Med.2016; 114: 84–90. DOI: 10.1016/j.rmed.2016.03.018.
  16. Loke Y.K., Cavallazzi R., Singh S. Risk of fractures with inhaled corticosteroids in COPD: systematic review and meta-analysis of randomised controlled trials and observational studies. Thorax. 2011; 66 (8): 699–708. DOI: 10.1136/thx.2011.160028.
  17. Nannini L.J., Cates C.J., Lasserson T.J., Poole P. Combined corticosteroid and long-acting beta-agonist in one inhaler versus placebo for chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. 2007; (4): CD003794. DOI: 10.1002/14651858.CD003794.pub3.
  18. Suissa S., Patenaude V., Lapi F., Ernst P. Inhaled corticosteroids in COPD and the risk of serious pneumonia. Thorax. 2013; 68 (11): 1029–1036. DOI: 10.1136/thoraxjnl-2012202872.
  19. Janson C., Larsson K., Lisspers K.H. et al. Pneumonia and pneumonia related mortality in patients with COPD treated with fixed combinations of inhaled corticosteroids and long acting β2-agonist: observational matched cohort study (PATHOS). Br. Med. J.2013; 346: f3306. DOI: 10.1136/ bmj.f3306.
  20. Kew K.M., Seniukovich A. Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease. Cochrane Database Syst. Rev.2014; (3): CD010115. DOI: 10.1002/14651858.CD010115.pub2.
  21. Yang I.A., Clarke M.S., Sim E.H.A., Fong K.M. Inhaled corticosteroids for stable chronic obstructive pulmonary disease.Cochrane Database Syst. Rev.2012; (7): CD002991. DOI: 10.1002/14651858.CD002991.pub3.
  22. Suissa S., Kezouh A., Ernst P. Inhaled corticosteroids and the risks of diabetes onset and progression. Am. J. Med. 2010; 123 (11): 1001–1006. DOI: 10.1016/j.amjmed.2010. 06.019.
  23. Ferreira A.J. et al. COPD: A stepwise or a hit hard approach?Rev. Port. Pneumol. 2016; 22 (4): 214–221. DOI: 10.1016/j.rppnen.2015.12.012.
  24. Kaplan A.G. Applying the wisdom of stepping down inhaled corticosteroids in patients with COPD: a proposed algorithm for clinical practice.Int. J. COPD.2015; 10 (1): 2535–2548. DOI: 10.2147/COPD.S93321. Поступила 28.02.17